Gitnux/Report 2026

API Industry Statistics

API Industry’s latest stats reveal how quickly usage and impact have shifted, with 2026 figures pointing to faster adoption and sharper performance expectations than the year before. If you want to understand where API demand is heading next and what that means for delivery, reliability, and growth, this snapshot makes the contrast impossible to miss.
257Statistics
82Sources
12Sections
1Visuals
45mRead
November 10, 2026Updated
API Industry Statistics
David KowalskiWritten by David Kowalski·Edited by Priya Chandrasekaran·Fact-checked by Peter Sandoval
Published ·Updated
How this report is researched
01Editorial Scope

An editor sets the topic, the inclusion criteria, and the evaluation framework before research starts.

02Source Research

AI search agents locate sources and extract each figure together with the document it came from.

Read our full methodology →

Search agents attach provenance to every extracted figure.

Next review: within 39 days

01 Industry overview

The api industry at a glance

The global active pharmaceutical ingredients market was valued at $270.5 billion in 2025 and is expanding as demand for generics, biologics, specialty drugs and supply-chain localization increases.

$270.5B[65]
Global market size, 2025
5.6%[65]
Forecast CAGR, 2026–2033
37.7%[65]
North America share, 2025
1,951[44]
U.S. API establishments, FY2025
Market size
The global active pharmaceutical ingredients market was valued at $270.5 billion in 2025. Grand View Research projects it will reach $419.0 billion by 2033.[65]
Forecast & CAGR
The market is forecast to grow from $287.1 billion in 2026 to $419.0 billion in 2033, representing a 5.6% CAGR from 2026 to 2033. A separate forecast estimates the market will reach $457.75 billion by 2034 at a 7.26% CAGR, reflecting differences in scope and methodology.[65][66]
Market share & regions
North America held the largest regional share at 37.7% in 2025, while Asia-Pacific was identified as the fastest-growing region. India’s API industry was estimated at about $13.5 billion in 2024, with approximately 65% of production consumed domestically and 35% exported.[65][67]
Segmentation
Synthetic APIs accounted for 70.9% of 2025 revenue, captive manufacturers held 50.6%, innovative APIs held 53.8%, cardiology represented 20.9% of application revenue, and prescription drugs accounted for 79.5%.[65]
Key players & concentration
The market includes integrated pharmaceutical manufacturers, merchant API suppliers and CDMOs, with major companies profiled including Lonza, Teva Pharmaceutical Industries, Zhejiang Huahai Pharmaceutical, Sun Pharmaceutical Industries and Aurobindo Pharma. In the United States, FDA data recorded 1,951 establishments registered solely as API establishments in FY2025, indicating a broad supplier base rather than a single-company market.[65][44]
Pricing
QYOBO’s API1000 index reported that 55% of tracked pharmaceutical ingredient prices decreased in 2025. Among selected peptide APIs, tirzepatide prices fell 55% and liraglutide prices fell 20%, while semaglutide increased 13%.[68]
Trends, drivers & challenges
Growth is being supported by chronic-disease treatment demand, biologics and biosimilars, specialty medicines and government efforts to localize pharmaceutical supply chains. Key challenges include dependence on concentrated overseas suppliers, regulatory compliance costs and shortages of critical ingredients; India imported $7.4 billion of APIs in 2025, with China supplying 84% of the total across the product categories tracked by NITI Aayog.[65][69]
Consumer behavior & competition
API demand is driven indirectly by prescription-drug volumes, generic substitution and the expansion of specialty and biologic therapies. Since 2015, an average of 59% of FDA-approved therapies have outsourced API production, increasing competition among specialized CDMOs and merchant suppliers for development and commercial contracts.[63]
M&A
M&A is concentrating capabilities in complex and high-potency APIs: HAS announced the acquisition of Cerbios-Pharma in 2025 to expand chemical, biological and antibody-drug-conjugate API manufacturing. CordenPharma also acquired AmbioPharm to broaden global peptide-API capacity, while Agno Pharma acquired Actylis’s Eugene, Oregon CDMO asset in January 2026.[23][70][71]
Regulation
API manufacturers supplying the U.S. market must comply with FDA current good manufacturing practice requirements, and FDA applies the same quality standards to domestic and foreign facilities. In FY2025, FDA reported 1,309 pharmaceutical-quality inspections, classified as 22% no action indicated, 60% voluntary action indicated and 18% official action indicated.[44]
Latest news
In 2026, API-sector expansion continued toward peptides, complex small molecules and U.S.-based manufacturing: Agno Pharma announced its acquisition of Actylis’s Eugene API and GMP-intermediate manufacturing asset in January, while CordenPharma’s AmbioPharm acquisition expanded peptide API capabilities.[71][70]

02 Ranking

Top 10 Companies in the Api Industry

The leading companies in the api industry, ranked on market impact, performance, momentum, innovation and brand popularity.

Updated November 10, 2026 · Next review December 10, 2026

Verdict

Lonza and Thermo Fisher Scientific are tied at the top of Gitnux's 2026 api ranking with an Overall score of 9.1 each.

Ranked by Overall score · How we score ↓

Editor's top 3 picks

Where to start, by need.

  1. #1 Overall · Leader in API CDMO

    Lonza

    CH

    Ranked #1 · 9.1 · API CDMO

    Why we picked it: Its global API and HPAPI development plus manufacturing scope aligns with synthetic and complex API demand.

    See in ranking ↓Visit lonza.com ↗

  2. Leader in generic API synthesis

    Divi’s Laboratories

    IN

    Ranked #3 · 9.0 · Generic API synthesis

    Why we picked it: It focuses on generic APIs and custom synthesis in India, matching broader generic substitution demand.

    See in ranking ↓Visit divislabs.com ↗

  3. Leader in complex API supply

    Dr. Reddy’s Laboratories

    IN

    Ranked #4 · 8.9 · Complex API supply

    Why we picked it: Its API business supplies more than 250 active pharmaceutical ingredients globally.

    See in ranking ↓Visit drreddys.com ↗

Pick 1 is the #1 company overall. Picks 2 and 3 are the highest-ranked companies in the top 5 that add a new segment.

Full ranking

Sort by
Top 10 companies in the api industry, 2026 – Gitnux ranking
#CompanyOverall ↓Company snapshot
1

Lonza

API CDMO · CH

9.1
2

Thermo Fisher Scientific

API CDMO · US

9.1
3

Divi’s Laboratories

Generic API synthesis · IN

9.0
4

Dr. Reddy’s Laboratories

Complex API supply · IN

8.9
5

WuXi AppTec

API CDMO · CN

8.9
6

Bachem

Peptide API manufacturing · CH

8.9
7

Pfizer

API CDMO · US

8.7
8

PolyPeptide Group

Peptide API capacity · CH

8.6
9

Siegfried

API CDMO · CH

8.4
10

Olon

API CDMO · IT

8.0

How we score

  • Impact (30%): scale and weight in the market (revenue, market share, employees, market position).
  • Performance (20%): recent revenue growth and operating margin; an analyst assessment where a company does not publish them.
  • Momentum (20%): growth trajectory and future potential.
  • Innovation (15%): R&D intensity and how technologically advanced the company is.

Popularity (brand search demand, 15%) counts toward Overall but is not published as a column. Overall leaves out what is not known.

Scale Scores are shown on a 7–10 scale with one decimal; bars start at 7.0.

Cadence Recalculated when new figures are published; next review December 10, 2026.

Independence. Rankings are editorially independent. Scores, ranks, picks and the verdict follow the method above; no company can pay to change them.

Cite this ranking

APA

David Kowalski. (2026, February 13). Top 10 companies in the api industry. In API Industry Statistics. Gitnux. https://gitnux.org/api-industry-statistics/#top-companies

report visual · Comparison

Indian active pharmaceutical ingredients industry market size

Indian active pharmaceutical ingredients industry market size: $19.3B in 2023, $19.3B in 2023.

2028 (forecast)$32.4B
2027 (forecast)$29.2B
2026 (forecast)$26.3B
2025 (forecast)$23.7B
2024 (forecast)$21.4B
2023$19.3B
source-verifiednsearchives.nseindia.com2028

04 Statistics

Technology & Innovation

R&D use of AI spans drug design, target identification and clinical-trial applications, while 75% of companies planned, piloted or deployed agentic AI in business operations.

AI in the api industry

  • 32% of AI or machine-learning contributions in pharmaceutical R&D supported drug design.[1]
  • 18% of AI or machine-learning contributions in pharmaceutical R&D supported precision medicine applications.[1]
  • 75% of pharmaceutical companies were planning, piloting or deploying agentic AI across business operations, according to a 2025 industry survey.[2]
  • 19 pharmaceutical trial starts involved AI or machine-learning companies in 2020.[1]
  • 31% of AI or machine-learning contributions in pharmaceutical R&D supported target identification.[1]
  • 13% of AI or machine-learning contributions in pharmaceutical R&D supported clinical-trial applications.[1]

Automation in the api industry

  • 418 pharmaceutical-industry professionals participated in ISPE’s 2023 Pharma 4.0 digital-transformation survey.[3]
  • Continuous upstream automation was highlighted as a strategic response to biopharmaceutical manufacturing workforce shortages in 2026.[4]

Digital Transformation in the software and IT services sector (sector benchmark)

  • 72% of digital leaders globally expected to increase technology spending in 2024, compared with 50% of digital laggards, according to a survey of 855 technology and business decision-makers.[5]
  • 54.8% of surveyed organizations reported having a chief digital officer or another executive responsible for digital transformation.[6]
  • 45% of North American technology and business decision-makers planned to adopt AI and machine learning to improve business within 12 to 24 months.[5]
  • 34% of surveyed organizations globally identified replacing or upgrading legacy technology as a top digital-transformation goal in 2024.[5]
  • 75% of digital leaders globally planned to increase AI-related business expenditure in 2024.[5]

Technology Adoption in the software and IT services sector (sector benchmark)

  • 57.7% of surveyed organizations reported having a chief information security officer or equivalent in 2024.[6]
  • More than 50% of surveyed global IT decision-makers were exploring AI use cases or piloting AI technologies in 2024.[5]
  • 67.6% of IT services were delivered through cloud infrastructure among surveyed organizations in 2024.[6]
  • 51.8% of surveyed organizations reported that AI solutions were somewhat or extremely rare in 2024.[6]

Cloud Computing in the software and IT services sector (sector benchmark)

  • 26.1% of EU enterprises using paid cloud services used computing platforms for application development, testing or deployment in 2025.[7]
  • 85.2% of EU enterprises using paid cloud services used them for email in 2025.[7]
  • 65.5% of EU enterprises using paid cloud services used them for security software applications in 2025.[7]
  • 52.7% of EU enterprises with at least 10 employees used paid cloud-computing services in 2025.[7]
  • 71.5% of EU enterprises using paid cloud services used them for file storage in 2025.[7]
  • 71.7% of EU enterprises using paid cloud services used them for office software in 2025.[7]

Big Data in the software and IT services sector (sector benchmark)

  • Big-data analytics adoption averaged 14% among OECD enterprises with at least 10 employees, compared with 49% for cloud computing in the latest comparable data.[8]
  • 40% was the highest reported enterprise adoption rate for big-data analytics across OECD countries in the latest available data through 2023.[8]
  • 14% of enterprises with at least 10 employees across the OECD used big-data analytics on average, based on 2022 data or the latest available year.[8]
  • 3% was the lowest reported enterprise adoption rate for big-data analytics across OECD countries in the latest available data through 2023.[8]

IoT in the software and IT services sector (sector benchmark)

  • 27% of enterprises with at least 10 employees across the OECD used Internet of Things technologies on average, based on 2023 or the latest available data.[8]
  • 27% of OECD enterprises used IoT technologies on average, compared with 49% using cloud computing in the latest comparable data.[8]
  • 6% was the lowest reported enterprise adoption rate for IoT technologies across OECD countries in the latest available data through 2023.[8]

05 Statistics

Data & Analytics

Business intelligence in the api industry

  • 13,752 Data & Analytics APIs were cataloged on APIs.io in 2026.[9]
  • 6 APIs were listed for Umami in the APIs.io business-intelligence catalog in 2026.[9]
  • 78 APIs were listed for Qlik Sense and Qlik Cloud in the APIs.io business-intelligence catalog in 2026.[9]
  • 14 published contracts were listed for GitLab in the APIs.io business-intelligence catalog in 2026.[9]
  • 11 APIs were listed for Power BI in the APIs.io Data & Analytics catalog in 2026.[9]
  • 2,184 Data & Analytics providers were cataloged on APIs.io in 2026.[9]

Data analytics in the api industry

  • 44 APIs were listed for Airbyte in the APIs.io Data & Analytics catalog in 2026.[9]
  • 55 APIs were listed for IBM in the APIs.io Data & Analytics catalog in 2026.[9]
  • 41 APIs were listed for New Relic in the APIs.io Data & Analytics catalog in 2026.[9]
  • 294 APIs were listed for Salesforce in the APIs.io Data & Analytics catalog in 2026.[9]
  • 34 APIs were listed for Dynatrace in the APIs.io Data & Analytics catalog in 2026.[9]
  • 31 APIs were listed for Plaid in the APIs.io Data & Analytics catalog in 2026.[9]

Data Quality in the software and IT services sector (sector benchmark)

  • In 2025, 46% of organizations globally said they were fully confident in their data quality, across surveyed technology and business organizations.[10]
  • In 2025, 35% of organizations globally rated their data excellent for consistency and standardization, across surveyed technology and business organizations.[10]
  • In 2025, 34% of organizations globally rated their data excellent for relevance and suitability, across surveyed technology and business organizations.[10]
  • In 2024, 95% of enterprise data leaders and practitioners reported a data-quality issue with a direct impact on business outcomes, across companies with at least $1 billion in revenue.[11]
  • In 2025, 46% of organizations globally rated their data excellent for accuracy and integrity, across surveyed technology and business organizations.[10]
  • In 2025, 43% of organizations globally rated their data excellent for quality and completeness, across surveyed technology and business organizations.[10]

Data Governance in the software and IT services sector (sector benchmark)

  • In 2024, 35% of U.S. technology executives prioritized data governance among their data-management areas for the next 12 months.[12]
  • In 2024, 18.3% of organizations reported having a data-governance or catalog solution as part of their governance program, according to a global governance study.[13]
  • In 2024, 81.7% of organizations reported having no data-governance or catalog solution as part of their governance program, according to a global governance study.[13]
  • In 2024, 32% of global technology leaders prioritized data governance among their data-management areas for the next 12 months.[12]
  • In 2026, 76% of global data leaders said their company’s AI governance did not completely keep pace with employee use of AI technology.[13]
  • In 2024, 61% of supply-management organizations reported having a dedicated data-governance function, based on an Institute for Supply Management survey.[14]

KPIs in the api industry

  • 42% of enterprises identified usage metrics as a capability for an effective API product in 2024.[15]
  • 55% of enterprise respondents reported directly monetizing APIs as part of their external ecosystem in 2024.[15]
  • 78% of enterprise decision-makers did not know how many APIs their organization had in its IT ecosystem in 2024.[15]
  • 33% of APIs were managed by a centralized operations team in the 2024 enterprise survey.[15]
  • 46% of decision-makers said stronger alignment between IT and line-of-business was needed for common API-program success in 2024.[15]
  • 35% of enterprises identified subscription plans as a capability for an effective API product in 2024.[15]

06 Statistics

Strategy & Growth

Growth is supported by contract and CDMO activity, with EUROAPI’s API Solutions revenue declining 8.8% in 2024 and CDMO activities at 27% of consolidated revenue.

Growth in the api industry

  • EUROAPI’s API Solutions revenue declined 8.8% to €663.6 million in 2024.[16]
  • EUROAPI added 37 new customers in 2024, according to its 2024 financial reporting.[17]
  • The global API market is projected to grow from $193.15 billion in 2023 to $285.29 billion by 2028.[18]
  • EUROAPI’s cross-selling strategy contributed approximately 9.5% of API Solutions sales to other clients in 2024.[17]
  • EUROAPI’s CDMO activities represented 27% of consolidated revenue in 2024.[16]
  • The global API market was valued at $285.2 billion in 2024 and is projected to reach $399.9 billion by 2029.[19]

Differentiation in the api industry

  • ANI Pharmaceuticals reported annual capacity of approximately 2.5 billion solid-dose units across its U.S. manufacturing footprint in 2026.[20]
  • EUROAPI had approximately 250 employees in its R&D team dedicated to industrial process development in 2025.[21]
  • EUROAPI reported 150 years of experience in the API market in 2025.[21]
  • EUROAPI’s portfolio included approximately 200 APIs in 2025.[21]
  • ANI Pharmaceuticals reported that approximately 95% of its revenues came from finished goods manufactured in the United States in 2026.[20]

Mergers and acquisitions in the api industry

  • Agilent completed its acquisition of BIOVECTRA, a Canadian CDMO specializing in biologics and highly potent APIs, in September 2024.[22]
  • HAS Healthcare Advanced Synthesis announced the planned acquisition of Cerbios-Pharma in March 2025 to expand chemical, biological API and antibody-drug-conjugate capabilities.[23]
  • Granules India completed its acquisition of Senn Chemicals on April 10, 2025 through its wholly owned subsidiary Granules Peptides.[24]
  • SPI Pharma completed the acquisition of 100% of Elementis Pharma GmbH in 2026.[25]
  • The acquired Actylis Eugene site includes a 16,000-square-foot R&D laboratory and a 30,000-square-foot GMP manufacturing facility.[26]
  • EUROAPI reported that its Brindisi API production suspension affected 2024 sales and growth.[17]

Strategic partnerships in the api industry

  • EUROAPI supplied approximately 30% of the APIs purchased by Sanofi in 2024.[16]
  • EUROAPI’s CDMO revenue from Sanofi was €112.7 million in 2024.[16]
  • EUROAPI had approximately ten projects with Sanofi focused on developing processes and manufacturing new molecular entities in 2024.[16]
  • EUROAPI’s CDMO revenue from customers other than Sanofi was €135.6 million in 2024.[16]
  • EUROAPI reported that CDMO partnerships represented 27% of consolidated revenue in 2024.[16]
  • EUROAPI’s 2021 master agreement with Sanofi covers development and GMP manufacturing services for APIs and intermediates.[16]

07 Statistics

People & Workforce

Workforce pressure shows up alongside remote and hybrid patterns. Hiring growth reached 1.7% and 5.7% year-over-year for October 2025 biopharmaceutical hiring and job demand.

Hiring in the api industry

  • Chemical equipment operators and tenders were among the five most common biopharmaceutical job categories in October 2025.[27]
  • 1.7% year-over-year growth in biopharmaceutical hiring was reported for October 2025.[27]
  • 5.7% year-over-year growth in biopharmaceutical job demand was reported for October 2025.[27]
  • More than 50% of bioprocessing-industry respondents reported significant hiring difficulties during the previous 15 years.[28]
  • Chemical technicians were among the five most common biopharmaceutical job categories in October 2025.[27]

Employee retention in the api industry

  • 9.4% was the 2024 turnover rate in Merck’s global human-health division.[29]
  • 6.9% was the 2024 turnover rate in Merck’s manufacturing division.[29]
  • 4.6% was Merck’s global voluntary employee turnover rate in 2024, down from 5.6% in 2023.[29]
  • 6.9% was Merck’s global overall employee turnover rate in 2024, down from 7.8% in 2023.[29]
  • 4.4% was the 2024 turnover rate in Merck’s research laboratories.[29]

Remote Work in the software and IT services sector (sector benchmark)

  • 6% of global respondents worked fully remotely in 2025, defined as spending less than one day per week in the office.[30]
  • 10% of technology-services respondents worked under fully flexible arrangements in 2025, allowing employees substantial control over remote work.[30]
  • 34.8% of global software and IT services respondents worked remotely in 2026, according to the Stack Overflow Developer Survey.[31]
  • 48% of U.S. software and IT professionals surveyed worked remotely in 2026, compared with 21% in France.[31]
  • 84% of technology-services employers agreed in 2025 that the ability to work remotely is important for employee retention.[30]

Hybrid Work in the software and IT services sector (sector benchmark)

  • 61% of U.S. employees with remote-capable jobs preferred hybrid work in November 2025, compared with 33% preferring fully remote work.[32]
  • 52% of U.S. employees with remote-capable jobs worked in hybrid arrangements in May 2026, according to Gallup.[32]
  • 47% of global respondents worked in hybrid arrangements in 2025, down from 63% in Cisco’s 2022 study.[30]
  • 56% of IT employees worked in hybrid arrangements in 2025, while 31% were fully remote and 13% attended the office daily.[33]
  • 55% of technology-services respondents worked in a hybrid arrangement in 2025, the highest share among industries measured by Cisco.[30]

Upskilling in the api industry

  • 26% growth in the pharmaceutical and life-sciences AI-skilled talent pool occurred between 2023 and 2024.[34]
  • 40% of pharmaceutical R&D professionals likely to leave cited lack of career development as a top-three reason for considering departure.[34]
  • Nearly 60% of pharmaceutical R&D professionals were at least somewhat likely to leave their current jobs within three to six months.[34]
  • 7% of pharmaceutical R&D professionals who changed jobs in 2024 moved into the medical-products industry.[34]
  • 15% growth in the overall pharmaceutical and life-sciences talent pool occurred between 2023 and 2024.[34]

Employee Engagement in the software and IT services sector (sector benchmark)

  • 74% of respondents approved of fully flexible hybrid policies in 2025, the highest positive sentiment among the policy types Cisco measured.[30]
  • 54% of exclusively remote U.S. employees were thriving in May 2026, compared with 52% of hybrid employees and 49% of on-site employees with remote-capable jobs.[32]
  • 22.2% of global software and IT respondents were happy with their current professional role in 2026, while 32.6% were unhappy.[31]
  • 92% of employees ranked collaboration and community as very important aspects of office culture in Cisco’s 2025 global study.[30]
  • 37% of exclusively remote U.S. employees were engaged in May 2026, compared with 34% of hybrid employees and 29% of on-site employees with remote-capable jobs.[32]

08 Statistics

Customer & Sales

API management influences commercial outcomes, with 69% of Middle Eastern organizations citing ineffective API management deteriorates user experience.

Customer experience in the api industry

  • 69% of Middle Eastern organizations surveyed said ineffective API management deteriorates user experience.[35]
  • 85% of respondents in a global API study said they were satisfied with customer experience in 2016.[36]
  • 97% of API decision-makers ranked improving customer experience as an API initiative priority in 2022.[15]
  • 68% of API decision-makers reported difficulty creating a good user experience for API onboarding and discovery in 2022.[15]
  • 65% of advanced API users reported delivering an improved customer experience, compared with 25% of limited API users, globally in 2016.[36]

Customer retention in the api industry

  • 62% of API advocates said their organizations were becoming platform providers partly to maintain customer stickiness in 2019.[37]
  • 60% of API advocates said APIs would have a major impact on customer upgrades or renewals in 2019.[37]
  • 53% of Middle Eastern organizations surveyed said ineffective API management causes customer churn to competitors.[35]

Customer acquisition in the api industry

  • 45% of surveyed API advocates identified “lead to customer” as an API use case in 2019.[37]
  • 72% of API decision-makers expected digital-business growth to increase if API adoption rose in 2022.[15]
  • 56% of Middle Eastern organizations surveyed said ineffective API management causes lost new-business opportunities.[35]

Customer loyalty in the api industry

  • 20% of surveyed API advocates identified “lead to loyalty” as an API use case in 2019.[37]
  • 62% of API advocates said their organizations were becoming platform providers to integrate with partners, maintain customer stickiness, or find new revenue in 2019.[37]

09 Statistics

Marketing & Brand

Organizations tied API programs to revenue and visibility, with 65% reporting generating revenue from API programs in 2025. API advocates cited CRM as a top API priority for 24% in 2019.

Marketing in the api industry

  • 24% of API advocates cited CRM as their top API priority in 2019.[37]
  • 59% of API decision-makers identified increased revenue as the top benefit of API-management products in 2022.[15]
  • 55% of API advocates said APIs were critical to their marketing or business strategy in 2019.[37]
  • 65% of organizations reported generating revenue from their API programs in 2025.[38]
  • 29% of API advocates said APIs were somewhat critical to their strategy in 2019.[37]

Digital marketing in the api industry

  • 74% of respondents used APIs to enable third-party developers in 2016.[36]
  • 76% of respondents in a global API study used APIs to build mobile applications in 2016.[36]
  • 36% of surveyed API advocates used APIs to build mobile products in 2019.[37]
  • 78% of respondents in a global API study used APIs to build web applications in 2016.[36]
  • 29% of surveyed API advocates used APIs to build B2C or consumer products in 2019.[37]

Influencer Marketing in the software and IT services sector (sector benchmark)

  • Across B2B companies, 55% of marketing organizations were using influencers in 2025, based on an Ipsos survey of 1,500 marketing leaders.[39]
  • Across B2B companies, 58% of marketing teams reported using an always-on influencer marketing approach in the 2025 B2B Influencer Marketing Report.[40]
  • Across technology companies, 27% of marketers reported dedicated but flat budgets for creator or influencer marketing in 2026, according to Nielsen’s global marketing survey.[41]
  • Across B2B companies, 43% of marketers reported outstanding results from their influencer programs in the 2025 B2B Influencer Marketing Report.[40]
  • Across technology companies, 64% of marketers reported dedicated and growing budgets for creator or influencer marketing in 2026, according to Nielsen’s global marketing survey.[41]

10 Statistics

Operations & Execution

Execution and compliance scale are central, with over 90% of FDA pharmaceutical inspections finding acceptable current good manufacturing practice compliance.

Process optimization in the api industry

  • 125+ integrated projects had been executed by Piramal Pharma over the five years through FY2024, supporting integrated API and drug-product manufacturing services.[19]
  • Approximately US$255 billion was the reported global API market size in 2024, with growth attributed partly to process innovation and operational efficiency.[42]
  • 30–40% is the typical overall yield for a six-stage primary pharmaceutical manufacturing process, according to an ACS Green Chemistry Institute industry presentation; global pharmaceutical manufacturing context, 2017.[43]
  • More than 40% of Piramal Pharma’s new service orders were integrated projects in FY2024, combining multiple development, API and drug-product services.[19]
  • 7% was the projected 2023–2030 growth rate for outsourced APIs, compared with 4% for captive API production, according to the Bain analysis cited by Divi’s Laboratories.[42]

Operational efficiency in the api industry

  • Over 90% of FDA pharmaceutical inspections found facilities to have acceptable current good manufacturing practice compliance, according to the agency’s current compliance summary.[44]
  • US$253 million was Piramal Pharma’s FY2024 revenue from differentiated CDMO offerings, including high-potency APIs, compared with US$139 million in FY2021.[19]
  • 17% was Piramal Pharma’s consolidated EBITDA margin in FY2024, compared with 12% in FY2023.[45]
  • 61% was Piramal Pharma’s year-on-year EBITDA growth in FY2024, attributed primarily to revenue growth, operating leverage, cost optimization and operational-excellence initiatives.[45]
  • 72% of API manufacturing facilities were identified by USP as relevant to continuous-manufacturing policy considerations, indicating the scale of the API facility base potentially affected by process modernization.[46]

Quality management in the api industry

  • 98% of European CDER sites had a most-recent inspection outcome of no action indicated or voluntary action indicated in FY2024.[44]
  • Zero official-action-indicated outcomes had been received by Piramal Pharma from the US FDA since 2011, according to its FY2024 annual report.[19]
  • 93% of Chinese CDER sites had a most-recent inspection outcome of no action indicated or voluntary action indicated in FY2024.[44]
  • 555 foreign FDA-conducted drug quality-assurance inspections were completed in FY2024, up from 397 in FY2023 and 146 in FY2022.[44]
  • 36 regulatory inspections were cleared by Piramal Pharma in FY2024 across its CDMO operations.[19]

Supply chain in the api industry

  • 1,268.56 million dollars was the total value of studied U.S. API imports from 2019 through 2024 in a tariff-impact analysis.[47]
  • 29,125 metric tons was the volume of studied U.S. API imports from 2019 through 2024 in a tariff-impact analysis.[47]
  • 36 companies was the average number licensed by FDA to market finished drugs using each API in the studied U.S. import sample.[47]
  • US$43.56 per kilogram was the weighted-average price of the studied API imports into the United States from 2019 through 2024.[47]
  • 544 Indian sites were represented in FDA’s FY2024 CDER Site Catalog, compared with 323 Chinese sites.[44]

Outsourcing / Offshoring in the software and IT services sector (sector benchmark)

  • Across European organizations, 35% planned to increase their use of nearshore outsourcing in the 2024/2025 sourcing study.[48]
  • Across EU enterprises sourcing business functions internationally during 2021–2023, 28.7% moved information and communication technology services abroad.[7]
  • Across German digital-experience service providers, 7.6% of services for customer projects were delivered offshore in 2024.[49]
  • Among German IT-service generalists, 10.2% of digital-experience services for customer projects were delivered offshore in 2024.[49]
  • Among German IT-service generalists, 19.5% of digital-experience services for customer projects were delivered nearshore in 2024.[49]

11 Statistics

Finance & Pricing

Pricing and unit-economics signals remain mixed, with 55% of tracked ingredient prices decreasing in 2025 and the weighted-average API import price at US$43.56 per kilogram.

Pricing strategy in the api industry

  • US$43.56 per kilogram was the weighted-average price of APIs imported into the United States in the 2019–2024 sample analyzed for tariff impacts.[47]
  • 15–25% was the reported price reduction for small-molecule API contract prices when branded-drug prices are cut, according to a U.S. API market analysis.[50]

Cost reduction in the api industry

  • 7% was the projected 2023–2030 growth rate for outsourced API production, whose expansion can support lower unit costs through greater manufacturing scale.[42]
  • US$150 million was invested by Piramal Pharma over two years through FY2024 in capacity additions, debottlenecking and technology upgrades intended to improve manufacturing economics.[19]
  • 4% was the projected 2023–2030 growth rate for captive API production, below the 7% rate projected for outsourced APIs.[42]

Profitability in the api industry

  • INR 1,372 crore was Piramal Pharma’s consolidated EBITDA in FY2024, up 61% from INR 853 crore in FY2023.[45]
  • 58% of Piramal Pharma’s FY2024 revenue came from its CDMO business, according to company-reported segment data.[51]
  • US$253 million was Piramal Pharma’s FY2024 revenue from differentiated CDMO offerings, including high-potency APIs and on-patent APIs.[19]
  • INR 8,171 crore was Piramal Pharma’s consolidated revenue from operations in FY2024, up 15% year on year.[45]
  • INR 4,750 crore was Piramal Pharma’s CDMO revenue in FY2024, representing 19% year-on-year growth.[45]

Financial planning in the api industry

  • 22% was the three-year CAGR through FY2024 for Piramal Pharma’s differentiated CDMO offerings, a planning indicator for its higher-complexity API strategy.[19]
  • US$150 million was Piramal Pharma’s investment in new capacity, debottlenecking and technology upgrades over the two years through FY2024.[19]
  • 25% was Piramal Pharma’s targeted operating margin for FY2030 as part of its long-term financial plan.[51]
  • US$2 billion was Piramal Pharma’s stated FY2030 revenue target, approximately double its FY2024 revenue level.[51]

12 Statistics

Product & Service

API practitioners report high testing activity (81% in 2025) and documentation (58%). Enterprises also reported sandbox support as a capability for an effective API product (36%).

Product development in the api industry

  • 81% of API practitioners worldwide reported testing as an API-related activity in 2025.[38]
  • 82% of organizations worldwide had adopted some level of API-first development in 2025, including 25% that were fully API-first.[38]
  • 58% of API practitioners worldwide reported documenting APIs as an API-related activity in 2025.[38]
  • 41% of API developers worldwide used AI to generate API documentation in 2025.[38]
  • 73% of API practitioners worldwide reported developing APIs as an API-related activity in 2025.[38]

Product lifecycle in the api industry

  • 34% of enterprises used only automated methods to catalog or maintain API records in 2024.[15]
  • 36% of API organizations worldwide used Grafana for monitoring in 2025.[38]
  • 26% of API organizations worldwide used semantic versioning in 2025.[38]
  • 30% of enterprises used only manual methods to catalog or maintain API records in 2024.[15]
  • 60% of API organizations worldwide versioned their APIs in 2025.[38]

After-sales in the api industry

  • 45% of enterprises identified technical documentation as a capability for an effective API product in 2024.[15]
  • 42% of enterprises identified business-level documentation as a capability for an effective API product in 2024.[15]
  • 36% of enterprises identified a testing sandbox as a capability for an effective API product in 2024.[15]
  • 47% of enterprises identified performance and SLA metrics as a capability for an effective API product in 2024.[15]
  • 20% of organizations worldwide used Elastic for API monitoring in 2025.[38]

Value proposition in the api industry

  • 43% of fully API-first organizations worldwide generated more than 25% of total revenue from APIs in 2025.[38]
  • 46% of organizations worldwide planned to increase API investment during the following 12 months in 2025.[38]
  • 23% of somewhat API-first organizations worldwide generated more than 25% of total revenue from APIs in 2025.[38]
  • 74% of organizations generating API revenue worldwide derived at least 10% of total revenue from APIs in 2025.[38]
  • 16% of non-API-first organizations worldwide generated more than 25% of total revenue from APIs in 2025.[38]

13 Statistics

Sustainability & Ethics

Water and solvents dominate manufacturing materials, with 87–91% of materials used in drug manufacturing processes. Waste and water metrics were considered important by 81% in an API-manufacturing review.

Sustainability in the api industry

  • 50% of the world’s top 30 pharmaceutical companies publicly highlighted water-related activities associated with API manufacturing in a 2020 review.[52]
  • 87–91% of materials used in drug manufacturing processes are water and solvents, with API synthesis identified as the most material-intensive stage; global evidence reviewed in 2026.[53]
  • 85% of pharmaceutical CDP respondents in 2020 said they engaged suppliers on shared water challenges.[52]
  • 18% of pharmaceutical CDP respondents in 2020 required more than half of their value chain to report water use and water-risk information.[52]
  • 83% of pharmaceutical companies responding to CDP in 2020 said they regularly undertook water-risk assessments.[52]

ESG in the api industry

  • 86% of respondents in an API-manufacturing sustainability review recognized carbon-dioxide emissions and energy-consumption metrics as important.[54]
  • Only a limited number of pharmaceutical companies publicly reported API-specific KPIs such as process mass intensity or waste metrics in the 2025 review.[54]
  • 81% of respondents in an API-manufacturing sustainability review considered waste and water metrics important.[54]
  • 107 API-manufacturing sites benefited from inspection reliance during the 2017–2024 international API inspection programme.[55]
  • 936 API-manufacturing sites were covered by inspection information shared through the international API inspection programme during 2017–2024.[55]

Circular economy in the api industry

  • No large-scale circular solutions for pharmaceutical packaging were identified in the OECD’s 2025 responsible-pharmaceuticals assessment.[8]
  • Increasing solvent recovery from 30% to 70% could reduce cradle-to-grave emissions for an API by 26%, according to a 2023 tenofovir-disoproxil-fumarate supply-chain study.[34]
  • Increasing solvent recycling to 97% could deliver an additional 17% reduction in cradle-to-grave emissions for the API studied in 2023.[34]
  • More than 2,000 active pharmaceutical ingredients are produced globally at roughly 100,000 tonnes per year, creating a major potential stream for pollution-prevention and circular-production measures.[8]

Carbon footprint in the api industry

  • Up to 90% of API-manufacturing carbon emissions could be reduced through a range of existing and emerging decarbonization solutions, according to a 2024 industry analysis.[34]
  • 26% of cradle-to-grave emissions for the API studied could be reduced by raising solvent recovery from 30% to 70%.[34]
  • 17% of additional cradle-to-grave emissions for the API studied could be avoided by increasing solvent recycling to 97%.[34]
  • Approximately one-quarter of pharmaceutical-company emissions can be attributed to manufacture of active pharmaceutical ingredients, according to a 2024 analysis.[34]

15 Statistics

Globalization & Expansion

Geographic mix shifts slowly, with North America at 37.7% share in 2025 and China supplying 84% of APIs in 2025 across categories tracked by NITI Aayog.

Globalization in the api industry

  • China supplied 8% of U.S. prescription-medicine API production volume in 2024, while the United States supplied 12%.[60]
  • 60.5% of global API production was located in Far East Asia in 2022, compared with 27.9% in Western Europe and 4.6% in North America.[18]
  • 4% of active API drug master files filed with the U.S. FDA in 2023 cited U.S. manufacturing facilities.[61]
  • 50% of active API drug master files filed with the U.S. FDA in 2023 cited manufacturing facilities in India, compared with 32% in China and 10% in the European Union.[61]
  • Half of U.S. prescription-medicine API production volume came from India and the European Union in 2024.[46]

Supplier management in the api industry

  • 23% of EUROAPI’s 2024 consolidated revenue came from customers excluding Sanofi that used the company as their exclusive API supplier.[16]
  • 55% of EUROAPI’s 2024 API Solutions revenue excluding Sanofi came from purchase orders, while 45% came from contractual relationships.[16]
  • EUROAPI’s ten largest customers excluding Sanofi represented 27.1% of consolidated revenue in 2024.[62]
  • 77% of small-molecule medicines approved by the U.S. FDA in 2024 used outsourced API manufacturing.[63]
  • 40% of surveyed pharmaceutical-industry respondents identified small-molecule API as the most outsourced product in July 2024.[64]

Distribution channels in the api industry

  • EUROAPI added 46 new customers across small- and large-molecule activities in 2023.[21]
  • EUROAPI’s API Solutions sales to customers other than Sanofi were €354.1 million in 2024, compared with €309.5 million in sales to Sanofi.[16]
  • EUROAPI generated €489.7 million of 2024 net sales from customers other than Sanofi and €422.2 million from Sanofi.[16]
  • EUROAPI’s CDMO sales to customers other than Sanofi were €135.6 million in 2024, compared with €112.7 million in sales to Sanofi.[16]
  • EUROAPI reported that customer destocking programs in Africa, Asia and Latin America partly offset API Solutions performance in 2023.[21]

Key questions about the API Industry

What is the global API market size in 2025?
The global active pharmaceutical ingredients market was valued at $270.5 billion in 2025.
How fast is the API market expected to grow after 2026?
The market is forecast to grow from $287.1 billion in 2026 to $419.0 billion by 2033, a 5.6% CAGR from 2026 to 2033.
Which companies lead the api industry?
Lonza and Thermo Fisher Scientific are tied at the top of Gitnux's 2026 api ranking with an Overall score of 9.1 each.
Where are technology shifts showing up in API workflows?
Enterprises reported testing as an API-related activity in 2025 (81%) and documenting APIs as 58%. Continuous upstream automation was highlighted as a response to biopharmaceutical workforce shortages in 2026.
How is the market structured across companies and facilities?
In the United States, FDA recorded 1,951 establishments registered solely as API establishments in FY2025, indicating a broad supplier base.
What pricing pressure indicators have appeared for APIs?
QYOBO’s API1000 index reported that 55% of tracked pharmaceutical ingredient prices decreased in 2025; tirzepatide fell 55% and liraglutide fell 20%.
Reference

Cite This Report

This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.

APA
David Kowalski. (2026, February 13). API Industry Statistics. Gitnux. https://gitnux.org/api-industry-statistics
MLA
David Kowalski. "API Industry Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/api-industry-statistics.
Chicago
David Kowalski. 2026. "API Industry Statistics." Gitnux. https://gitnux.org/api-industry-statistics.

Sources & references

82 sources cited across this report

  1. makingpharmaindustry.it
  2. statics.globant.com
  3. ispe.org
  4. biopharminternational.com
  5. teksystems.com
  6. higherlogicdownload.s3.amazonaws.com
  7. ec.europa.eu
  8. oecd.org
  9. apis.io
  10. riverbed.com
  11. anomalo.com
  12. kpmg.com
  13. informatica.com
  14. utah.ismworld.org
  15. blog.axway.com
  16. financialfilings.com
  17. pappers.fr
  18. hub.unido.org
  19. nsearchives.nseindia.com
  20. sec.gov
  21. euroapi.com
  22. agilent.com
  23. hashealthcare.com
  24. sennchem.com
  25. spipharma.com
  26. agnopharma.com
  27. toptal.com
  28. cdn.cytivalifesciences.com
  29. merck.com
  30. newsroom.cisco.com
  31. survey.stackoverflow.co
  32. gallup.com
  33. computerworld.com
  34. mckinsey.com
  35. cdn.studio.f5.com
  36. cioreview.com
  37. mediapost.com
  38. postman.com
  39. business.linkedin.com
  40. toprankmarketing.com
  41. brand-news.it
  42. divislabs.com
  43. acs.org
  44. fda.gov
  45. piramal.com
  46. usp.org
  47. pmc.ncbi.nlm.nih.gov
  48. whitelane.com
  49. luenendonk.de
  50. mordorintelligence.com
  51. economictimes.indiatimes.com
  52. wwfint.awsassets.panda.org
  53. frontiersin.org
  54. pubs.acs.org
  55. ema.europa.eu
  56. gtia.org
  57. isc2.org
  58. cdn.sypher.eu
  59. pagerduty.com
  60. govinfo.gov
  61. raps.org
  62. db.srnav.com
  63. williamblair.com
  64. glginsights.com
  65. grandviewresearch.com
  66. fortunebusinessinsights.com
  67. icra.in
  68. qyobo.com
  69. niti.gov.in
  70. ambiopharm.com
  71. finance.yahoo.com
  72. lonza.com
  73. thermofisher.com
  74. api.drreddys.com
  75. wuxiapptec.com
  76. marketsandmarkets.com
  77. siegfried.ch
  78. cordenpharma.com
  79. mdpi.com
  80. pharmamanufacturing.com
  81. theprint.in
  82. linkedin.com